28-30 April Liverpool
1-EP | Characterization of Acute Promyelocytic Leukaemia: follow up study at a tertiary care center | Maymoona Suhail | Received |
2-EP | c-MYC gene expression in hematological malignancies: Diagnostic and prognostic value | Ifeyinwa Okafor | Received |
3-EP | RELATIONSHIP OF ENDOGENOUS CYTOKINES TNF, TGF1 IN ACUTE MYELOBLASTIC LEUKEMIA WITH SEVERITY OF CYTOPENIA | Vira Barilka | Received |
4-EP | How Does Chemotherapy Affects Elderly AML Patients? | Manal Aboelmagd | Received |
5-PO | Physical Isolation of Tumour Associated ctDNA Fragments for Novel AML Liquid Biopsy | Maisie Spurling | Received |
5-EP | Acute Myeloid Leukaemia in Adolescents and Young Adults: A Distinct Entity? | Mohamed H. Omer | Received |
8-EP | Real-World Data on Venetoclax-Based Non-Intensive Chemotherapy for AML in an Elderly, Rural Population | Martha Vickers | Received |
9-EP | Precise FISH panels guided by population prevalence may assist pragmatic diagnosis of Ph-like ALL | Jane Thompson | Received |
10-EP | Identifying low risk AML patients on Azacitidine and Venetoclax that do not require inpatient monitoring | Verigou Eleni-Anna | Received |
11-EP | An Observational Study of AML Patients Treated with Vyxeos Chemotherapy - A Single Centre | Matthew Duffy | Received |
12-EP | Long Term Outcomes of Stem-Cell-Transplant in Older Patients with AML treated with Venetoclax HMA Therapies | Kathryn Moulton | Received |
13-EP | A Multiomic, Single-Cell Measurable Residual Disease (SCMRD) Assay For Phasing DNA Mutations And Surface Immunophenotypes | Matteo Cattaneo | Received |
14-EP | Morbidity and Mortality Outcomes in Acute Myeloid Leukaemia Patients Treated with Venetoclax and Azacitidine Chemotherapy | Francesca Leonforte | Received |
15-EP | Palliative haematology clinic for patients with Bone Marrow failure syndromes and Acute Myeloid Leukaemia. | Jayne Osborne | Received |
16-EP | Review of the Acute Leukaemia Services at a District General Hospital | Ethan Wong | Received |
17-EP | Real-world Experience of Venetoclax with Azacitidine or Cytarabine for the Treatment of Acute Myeloid Leukaemia | Emily Sutherland | Received |
18-EP | High Survival Rate in Haematology Patients Admitted to ICU in a Tertiary Referral Centre | Hannah Sadler | Received |
18-PO | Variants in Development of Pure Red Cell Aplasia & Treatment Approaches:Single Centre Study in UK | Sukanya Gogoi | Received |
19-PO | Venetoclax Azacitadine as First Line Treatment for AML Real-World Data from a Multi-Centre Study | Holly Gilbert | Received |
19-EP | Real-world Outcomes for Patients with Acute Myeloid Leukaemia treated with Venetoclax-Azacytidine in North of England | Yashashree Gupta | Received |
20-EP | IKZF1 Deletion in Acute Lymphoblastic Leukemia: a Single-Center Experience in Thailand | Suchada Sommaluan | Received |
20-PO | Elucidating the S100A4-Mediated Mechanisms Promoting AML Blast Proliferation and Survival | Rehab Alanazi | Received |
22-EP | Targeting NOX2 Overexpression in Acute Myeloid Leukaemia using In Vitro Models | Sian Rizzo | Received |
22-PO | The Benefit of Nurse Led Group End of Treatment Summary Sessions for Patients. | Nicola Goffinet | Received |
23-EP | Phase 3b Design: Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Patients with Leukaemias | Hemal Parmar | Received |
24-EP | Outcomes of Venetoclax based therapy for AML Patients - A UK DGH Real World Experience | Olamide BELLO | Received |
25-EP | How Much Is Too Much? Audit of Routine Biochemistry Requests For AML Inpatients on Chemotherapy | Tioluwanimi Ojeola | Received |
26-EP | Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia | David Allsup | Received |
27-EP | Deciphering The Puzzle: Acute Leukaemias of Ambiguous Lineage | Maymoona Suhail | Received |
28-EP | Are CCL19 and CCL21 the keys to unlocking dendritic cell function in paediatric B-ALL? | Thomas Daley | Received |
30-EP | The relationship between early diagnosis and treatment of suspected secondary HLH (Haemophagocytic lymphohistiocytosis) on patient survival outcomes: a case series. | Taran Nandra | Received |
30-PO | Exploring perceptions in management and treatment of polycythaemia vera (PV) in the UK: PV-PINPOINT study | Mary Frances McMullin | Received |
31-EP | Preventative information (regarding Mucositis) given to Paediatric Patients awaiting Bone Marrow Transplants: A QI Project | Alisha Amin | Received |
32-EP | Referrals to a haematology day unit: has the quality improved with a new electronic system? | Sophie Ralston | Received |
33-PO | Rare MPIG6B Gene Mutation cause of refractory severe thrombocytopenia with myelofibrosis in adolescent. | Muzna Aquil | Received |
34-EP | Basics to Brilliance: A Haematology Podcast for Trainees | David Fasey | Received |
35-EP | Bilateral Retrobulbar Hemorrhage Causing Spontaneous Globe Subluxation in a Pediatric Patient with Factor XIII Deficiency | H Shafeeq Ahmed | Received |
36-PO | Application of Prognostic Scoring in Advanced Systemic Mastocytosis patients and the Impact of Novel Therapies | Priya Sriskandarajah | Received |
37-EP | Rosai-Dorfman Disease - a Rare Histiocytic Disorder : A Single Centre Experience Rosai-Dorfman Disease - A Rare Histiocytic Disorder : A Single Centre Experience. | Menna Shamma | Received |
38-EP | Adhering to best practice in a nurse led myeloproliferative clinic. | Emma Whitham | Received |
39-EP | Dark Web Deception: Using Laboratory Haematology to Resolve a Case of Unexplained Coagulopathy | Eleanor Sheppard | Received |
40-EP | Interesting case report: Acute thrombocytopaenia following an overseas renal transplant | Aoife Dervin | Received |
40-PO | An Audit of Corticosteroid use in ITP at Kings College Hospital NHS Trust | Rosalind Byrne | Received |
41-EP | Peri-operative anaemia optimisation since the Covid pandemic - a service evaluation | Amjad Hmaid | Received |
41-PO | Diagnosis and Treatment Patterns in European Patients with Systemic Mastocytosis | Marisa Vincenti | Received |
42-PO | Burden of Systemic Mastocytosis in Europe and the UK: Interim Results from PRISM Patient Survey | Marisa Vincenti | Received |
42-EP | Phase 3 Randomized Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in JAKi-Naïve Myelofibrosis | Jennifer OSullivan | Received |
43-PO | A Single-site Audit of Treatment Free Remission Identification and Monitoring in Chronic Myeloid Leukaemia Patients | Sophie Evans | Received |
43-EP | The Burden of Anaemia in a Primary Care Population in UK: what is Haematologys Role? | Suzanne Maynard | Received |
44-EP | Exceptionally High Prevalence of Iron Deficiency Anaemia in Children Residing in Rural Areas in Pakistan | Baig Aleena | Received |
45-EP | VAMPIRC: Venesection Audit in the Midlands for secondary Polycythaemia Investigating thRombotic Complications | Caroline Morgan | Received |
46-EP | Outcome of bone marrow examinations in children with isolated thrombocytopenia: Experience from LMIC | Visvalingam Arunath | Received |
47-EP | Hyperhaemolysis Syndrome in a Young Patient with Autoimmune Haemolytic Anaemia | Nayanathara Silpage | Received |
48-EP | Quality improvement and resource optimisation - Subcutaneous Immunoglobulin for secondary immunodeficiency associated with haematological disorders | Amira Chaudry | Received |
48-PO | Overview of Erythrocytosis and Thrombocytosis referrals within General Haematology clinics streamlining the MPN service | Xavier Peer | Received |
49-EP | Use of Low Dose Naltrexone and Hydroxycarbamide for Mast Cell Disorders (SM, MCAS & HaT) | Bethan Myers | Received |
50-EP | Investigation of Isolated Neutropenia in Childhood: Aetiology and Outcomes | Eoghan Dunlea | Received |
51-EP | Treatment Free Remission in CML Patients on TKIs: An Audit From A London DGH | Augustus Diaz | Received |
52-EP | Two years of the Genomic Haematology clinic: outcomes from a new service for South-West England | Sarah Westbury | Received |
54-EP | Pegylated Interferon in Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ringed Sideroblasts and Marked Thrombocytosis: Single-Centre Case Series | Mohammed Altohami | Received |
55-EP | Safety and Efficacy of Low Dose Pegylated Interferon (PEG-IFN) in Myeloproliferative Neoplasms: Real World Data | Mamta Garg | Received |
56-EP | Detection and management of iron deficiency in pregnant women who had a major obstetric haemorrhage | Adrian Choy | Received |
56-PO | Exploring Prognostic Factors in Myeloproliferative Neoplasms-associated Splanchnic Vein Thrombosis | Elena Torre | Received |
58-EP | More Than Just a Number: Impact of ITP on Psychosocial QoL in Pediatric Patients | Nazia Mumtaz | Received |
59-EP | Myeloproliferative Neoplasms and Thrombosis A Single Centre Retrospective Cohort Study of 111 Cases | Rupen Hargreaves | Received |
60-EP | Real-World, Single-Centre Experience of Pregnancy in Patients with Philadelphia Negative Myeloproliferative Neoplasms | Holly Theaker | Received |
61-EP | Chronic myelogenous leukemia presenting with Morel Lavallee lesion case report | Gebeyehu Tessema Azibte | Received |
62-EP | Use of new third-line therapy for myeloproliferative neoplasm with concurrent BCR-ABL1 translocations and JAK2-V617F mutation | Thais Ferrari Gersogamo | Received |
63-EP | A Real-World Patient Experiences and Quality of Life Insights Snapshot in Cold Agglutinin Disease (CAD). | Kim Summers | Received |
64-PO | Deaths Attributable to Transfusion-Associated Circulatory Overload: 10-year Review of Serious Hazards Of Transfusion (SHOT) Data | Oliver Firth | Received |
64-EP | Real-world electronic data in a haematology centre to better understand patient and care activity | Simon Stanworth | Received |
65-EP | Stopping TKI-therapy in CML as per the BSH guidelines, an audit from a DGH practice | Shyamala Chinnabhandara | Received |
65-PO | Clinical and cost effectiveness of cell salvage use in complex spinal surgery | Thomas Burton | Received |
66-PO | Understanding the use of CMV-seronegative blood in allogeneic-HSCT in England | Oliver Firth | Received |
66-EP | Refining Ph-MPN Diagnostic Pathways: Insights from an Audit of Wales Medical Genomics Service | Leila Alwadi | Received |
68-PO | Alloimmunisation in Sickle Cell Disease: a 3-year Retrospective Study in a Tertiary Haemoglobinopathy Treatment Centre | Kate Fletcher | Received |
69-EP | Patient Experience, Quality of Life and Unmet Need in UK CML Community | Andrea Preston | Received |
71-EP | Navigating the Storm: Adherence and Management of Polycythaemia Vera through the COVID-19 Pandemic. | Benjamin Lim | Received |
72-EP | PACIFICA: A Randomized, Phase 3 Study of Pacritinib Versus Physicians Choice in Patients with Myelofibrosis | Claire Harrison | Received |
73-PO | Large Cell Transformation of Mycosis Fungoides: Patterns of Care and Patient Outcomes | Philippa Johnstone | Received |
73-EP | An Audit of Use of Intravenous Immunoglobulin Therapy in Haemato-Oncology Patients | Dario Melotti | Received |
75-EP | Evidence of Relevant Anaemia Response in Myelofibrosis Patients with Impaired Renal Function Treated with Momelotinib | Kyaw Htin THAW | Received |
76-EP | Randomized, Open-Label Phase 3 Study of the Lysine-Specific Demethylase 1 Inhibitor Bomedemstat for Essential Thrombocythaemia | Rushdia Yusuf | Received |
76-PO | Updated Results of the Safety Run-in of the Phase 3 LOTIS-5 Trial | Yvonne Law | Received |
77-EP | Parathyroid hormone in plasmodium berghei infection | Kavyesh Vivek | Received |
79-EP | Prevalence of ABO and RhD blood group system among blood donors in Blood Centre Batticaloa. | Gauri Jayasinghe | Received |
80-EP | Influencing Change in Transfusion Information Technology Systems - the SCRIPT Survey and Collaborative Working Project | Victoria Tuckley | Received |
81-EP | Role of Therapeutic Plasma Exchange in a Child with Secondary Haemophagocytic Lymphohistiocytosis | Nayanathara Silpage | Received |
82-EP | Audit on the Usage of O RhD-Negative Red Cells in Emergencies in a Tertiary Hospital | Sai Lon Wann | Received |
83-EP | Hematological Predictors of No-Reflow in Patients Undergoing Primary PCI For STEMI. | Dr Shereen Elshazly | Received |
83-PO | Phase 2 Trial of Nanatinostat and Valganciclovir in Patients with EBV-Positive (EBV) Relapsed/Refractory Lymphomas (NAVAL-1) | Jacqueline Jessie | Received |
84-EP | DNA extracted from cultured cells as a source of survey material for Molecular Haemoglobinopathy EQA | Bashori Rahman | Received |
85-PO | Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma | Huseini Kagdi | Received |
85-EP | Evolving Caseload of Adult Bone Marrow Biopsies in a Specialist Integrated Haematological Malignancy Diagnostic Service | jake tobin | Received |
86-PO | Pirtobrutinib in Prior cBTKi R/R MCL: Phase 1/2 BRUIN Study Updates including High-Risk Subgroup Analyses | Huseini Kagdi | Received |
86-EP | Patient Consent for Blood Transfusion: An Audit | Zoe Rose | Received |
87-EP | The CD47-Blocking Immune Checkpoint Inhibitor Maplirpacept Does Not Interfere with Blood Transfusion Compatibility Testing | Simon Purcell | Received |
88-EP | Pathology Portal: Developing a novel, interactive education portal for Transfusion Medicine | Matthew Poynton | Received |
88-PO | Infectious complications of bispecific antibody treatment in patients with lymphoproliferative disorders | Abigail Martin | Received |
90-PO | Epcoritamab GemOx in ASCT-ineligible patients with R/R DLBCL: updated results from EPCORE NHL-2 | David Lewis | Received |
90-EP | Insights on Erythrocyte Alloimmunization and Auto-immunization in Children from North India | Manish Raturi | Received |
91-EP | CDK1 Inhibitor RO-3306 Enhances BTKi Potency in Diffuse Large B-cell Lymphoma by Suppressing JAK2/STAT3 Signaling | Qiuni Chen | Received |
92-EP | Type 1 Cryoglobulinemic Vasculitis Associated with Marginal Zone Lymphoma Successfully Treated with Bendamustine and Rituximab | Apurwa Prasad | Received |
92-PO | Mitigating the risk of cytokine release syndrome: EPCORE NHL-1 DLBCL cycle 1 optimization cohort results | Kim Linton | Received |
93-EP | Modified DHAP Salvage Therapy for Refractory &/or Relapsed Classic Hodgkins (CHL) and Non-Hodgkins Lymphomas (NHL) | Yasmine Shaaban | Received |
94-EP | Identification of Plasma lncRNA for Bone Marrow Infiltration and Staging in Diffuse Large B-Cell Lymphoma | Samar Sami Elshazly Elshazly | Received |
95-EP | Diffuse B-large cell non-Hodgkins lymphoma(DBCL) associated with hepatitis B virus(HBV), clinical characteristics, therapy, and prognosis. | Sergey Lepkov | Received |
96-EP | Regional Case Series of Grey Zone Lymphoma Outcomes | Euan Haynes | Received |
97-PO | Awareness, Knowledge, and Acceptance of Bone Marrow Transplantation for Beta Thalassemia Major in Sri Lanka | Heroshan Hasintha Jayakadu Jayakadu mudiyanselage | Received |
98-EP | DAAA therapyin patients with hepatitis C associated indolent non-Hodgkin lymphomas(HCVINHL) results of prospective study | Sergey Lepkov | Received |
99-EP | Improving bone health in lymphoma- DGH experience | Saima Afridi | Received |
100-EP | Patient Initiated Follow-Up in Lymphoma: Reducing clinic appointments, cost and environmental impact | Emily Buchanan | Received |
101-EP | Night Sweats as a Referral Criterion for Suspected Lymphoma in the Post-COVID Era | Charlotte Dawson | Received |
102-EP | A Review of a District General Hospital Lymphoma Service Before and After the COVID19 Pandemic | Yen Huan Yeo | Received |
103-PO | Klebsiella Liver Abscesses in Paediatric Haemoglobinopathy Patients on Transfusion-Chelation Regimen | Bethany Singh | Received |
103-EP | Epidemiological Analysis of Hodgkins Lymphoma in a Developing Middle Eastern Country Over 18 Years | Ahmed Abdulelah | Received |
104-PO | Transcranial Doppler Screening of Children With Sickle Cell Disease in the HOPE Kids 2 Trial | Jack Jung | Received |
104-EP | Epidemiological Analysis of Non-Hodgkins Lymphoma in a Developing Middle Eastern Country Over 18 Years | Ahmed Abdulelah | Received |
105-PO | Over 4 Years of Safety and Efficacy With Voxelotor in Patients with Sickle Cell Disease | Jack Jung | Received |
105-EP | A multiplexed fluorescent immunohistochemical analysis of CXCR4/CXCL12 axis in de novo and CNS B-cell lymphoma | TAN JIAO JIE CHERIE | Received |
106-EP | A Child with Sporadic Burkitt lymphoma presenting as acute flaccid paralysis and capillary leak syndrome | Visvalingam Arunath | Received |
107-EP | Axicabtagene Ciloleucel Real-World Manufacturing Experience in the United Kingdom | Vaishali Dulobdas | Received |
108-PO | Real-World Patient Awareness Around Emerging Gene Therapies: Implications for Barriers to Access. | Kim Summers | Received |
109-PO | Serum Soluble VCAM-1 is Not Associated with Severity of SCD in Adult Ghanaian Patients | Willliam Ghunney | Received |
109-EP | Single Centre Experience of Personalised Stratified Follow-Up for Patients with Lymphoma Treated with Curative Intent | Sapna Ladani | Received |
110-EP | Diffuse B-large cell non-Hodgkins lymphoma associated with hepatitis C (HCVDBCL): clinic and therapy results | Sergey Lepkov | Received |
111-EP | Pilot for Speeding up the Diagnosis of Lymphadenopathies | Gillian Flynn | Received |
112-EP | Elderly Patient With Hematological and Neurological Manifestations of Undetermined Origin: A Diagnostic Dilemma of Pernicious Anemia | Anas Ibraheem | Received |
112-PO | Efanesoctocog Alfa Prophylaxis Outcomes in European Patients From the XTEND-1 Trial | Mark Smith | Received |
113-EP | Preoperative Transfusion in Patients with Sickle Cell Disease: Systematic Review & Meta-analysis | Khalid Elhag Mohamed Ahmed Ahmed | Received |
114-EP | Causal relations between autoimmune diseases and aplastic anemia: a bidirectional two-sample Mendelian randomization study | Qiuni Chen | Received |
114-PO | Overview of the Effect of Anticoagulants on Heavy Menstrual Bleeding in Women with Thrombosis | Rawya Hussein | Received |
115-EP | Severe B12 Deficiency Mimicking HELLP Syndrome; A Case Report | Aneesa Rameh | Received |
116-EP | Use of Conventional Transfusion Thresholds Contribute to Iron Overload in Patients with Sickle Cell Disease | Niravkumar Brahmbhatt | Received |
118-EP | METHEMOGLOBINEMIA A CASE REPORT | Zahra Hasan | Received |
119-EP | Design and Implementation of sickle cell disease electronic registry in limited resources setting in Nigeria | Muhammad Aminu Idris | Received |
120-EP | Minimizing Alloimmunization: Rethinking Blood Transfusions in Acute Chest Syndrome Management | Melissa Friday | Received |
121-EP | Dapsone induced haemolytic anaemia and methemoglobinemia in a paediatric case study | EMILY BROAD | Received |
122-EP | Between The Extremes .. A Case report of polycythemia Vera post autoimmune haemolytic anemia | Asmaa Mohsen | Received |
123-EP | Management of obstetric patients with sickle cell disease a case series | Ismini Panayotidis | Received |
124-EP | Is Umbilical Cord Blood a Better Treatment for Treating Paediatric Patient with Sickle Cell Disease | Ebehiremen Ebhodaghe | Received |
125-EP | Treatment of Autoimmune Hemolytic Anemia in Beta Thalassemia Major | Gulab Fatima Rani | Received |
126-EP | Pharmacological Intervention for Pain Management in Paediatric Sickle cell Anaemia Patient: A Network Meta-Analysis | Nabiel Muhammad Haykal | Received |
128-EP | Evaluation of Some Haemostatic Parameters in Management of HBV Infection Treatment Outcome in Asaba Nigeria. | Sylvia Obu | Received |
132-EP | An audit of laboratory practice conformance with guidelines for antiphospholipid tests | Sophie Moores | Received |
133-PO | Real-World Data for the Efficacy and Safety of Acalabrutinib Across Two Centres in East England | Edward Benn | Received |
134-EP | Hyperhomocysteinemia-associated Thrombosis in Patients With Pernicious Anemia | Thura Htut | Received |
135-EP | An Audit to Assess Venous Thromboembolism Prevention Management in Pregnant/Postpartum Hospital Inpatients | Clarissa Pui | Received |
136-EP | An Audit to Assess Venous Thromboembolism Prevention Management for COVID-19 Positive Hospital Inpatients | Clarissa Pui | Received |
137-EP | A Review of Hospital-Associated Thrombosis with a Shared Learning Dashboard | Clarissa Pui | Received |
138-EP | Von Willebrands disease and gastrointestinal angiodysplasia: a case series from a haemostasis and thrombosis centre | Chloe Merrion | Received |
139-EP | Root Cause Analyses of Deaths Associated with Hospital-Acquired Venous Thromboses Over Twelve Months | Kaysar Mohammadi | Received |
140-EP | Evaluation of D-dimer Cut-Off Levels for VTE Diagnosis in a Tertiary Centre | Ala Bawazir | Received |
140-PO | Final Results: Phase 1b Study of Subcutaneous Isatuximab Administration by OBDS Plus Pomalidomide-dexamethasone in RRMM | Nicholas Burnley-Hall | Received |
141-PO | 30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma Patients: Results of Phase 1b Study | Sheetal Fermahan | Received |
141-EP | Time-in-Therapeutic Range (TTR) falls as the INR range increases in patients on warfarin | Imran Malik | Received |
142-EP | Variation of monitoring for Vitamin K antagonist in antiphospholipid syndrome (APS) | Saniya Khakwani | Received |
143-EP | Venous Thromboembolic Events in a Scottish District General Hospital: Variation in Management and Significant Recurrence | Philippa Stimpson | Received |
145-EP | Magnetic Nanoparticles: the Possibility of Applications in the Technology of Purification of Factor VIII Coagulation | Nataliya Shurko | Received |
146-EP | Audit of Comprehensive Care of Haemophilia B against World Federation of Haemophilia Guidelines. | Jayna Mistry | Received |
147-EP | Antiphospholipid Syndrome Vasculopathy with Severe Aortic Stenosis | Dina Osman | Received |
148-PO | Single-Cell Multi-Omic Correlation of SNVs, CNV and Surface Epitopes for Clonal Profiling of Myeloma | Matteo Cattaneo | Received |
148-EP | Investigating The Utility and Clinical relevance of Thrombin Time | Rishabh Motiwale | Received |
149-EP | Managing Pelvic Intraperitoneal Bleed Secondary to Ovulation in Adolescents with Congenital Bleeding Disorders. | Pallav Rakesh | Received |
151-PO | Pirtobrutinib and Venetoclax Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated BRUIN Phase 1b Results | Huseini Kagdi | Received |
152-EP | Cost-efficiency of home treatment/early discharge low risk patients with pulmonary embolism in a low-income country | Galina Sorici | Received |
153-EP | Healthcare Resource Utilisation of Patients with VWD Treated with Recombinant Von Willebrand Factor: Chart Review | Ollie Heard | Received |
154-EP | A 13-month Audit on Adherenceand Outcomes of Bridging Therapy at a UK Tertiary Centre | Hassan Mahfouz | Received |
155-EP | The consequences of delayed diagnosis of pulmonary embolism, a comparative study | Nadejda Diaconu | Received |
156-EP | Prospective Data Collection Project to Facilitate Audit in the Nurse-Led DVT Service | Rebecca Cloudsdale | Received |
157-EP | VTE associated with N2O Use: No Laughing Matter | Aizzah Mahmood | Received |
158-EP | Evaluation Astrazanica Vaccine of COVID-19 on PT, APTT Among Sudanese Vaccinated | Abdelrahim Sara | Received |
159-EP | Comparison between CMV viraemia in Fully Matched and Haploidentical Stem Cell Transplants in Acute Leukaemia. | Asmaa Mohsen | Received |
160-EP | Utility of PBSC collection post salvage chemotherapy for relapsed and refractory lymphomas-A single centre study | Nkemdirim Ernest Jacob | Received |
161-EP | EARLY CRS PREDICTING ICANS AND ACUTE INFECTIONS PREDICTING PROGRESSION IN DLBCL PATIENTS RECEIVING CAR-T THERAPY | Khalil Begg | Received |
162-EP | Integration of palliative care with CAR T services a first year experience | Maimoona Ali | Received |
163-EP | Positive Complement Dependent Cytotoxicity Crossmatch following Covid 19 Vaccination in a Patient awaiting Renal Transplantation | Induni Gallage | Received |
164-EP | Evaluation of Apheresis Parameters for Optimal Autologous Peripheral Blood Stem Cell Harvesting from Lymphoma Patients | Dilupa Gunasekara | Received |
165-EP | Characteristics, prognostic indicators and survival Among Omani Patients Diagnosed With Chronic Lymphoid Leukemia at SQUH | Salim Al Ruqeishi | Received |
166-EP | Rituximab Prior To Venetoclax Is Safe And Effective In Relapsed/Refractory Chronic Lymphocytic Leukemia | Peter Johnstone | Received |
167-EP | A Retrospective Review of SPEP Testing Practices and MGUS diagnosis in a Community Hospital | Chun Siu | Received |
168-EP | Diagnostics and treatment in AL Amyloidosis with Cardiac Involvement- A Dual Centre Retrospective Cohort Study | Ewan Evans | Received |
169-EP | Investigating Infection in Multiple Myeloma Patients on Anti-CD38 Monoclonal Antibody Treatment | Hannah Furness | Received |
170-EP | Triple Class Refractory Patient and Carer Experience of Living with Multiple Myeloma | Noreen Ali | Received |
172-EP | Switching From Covalent BTKi to BCL2i Improves Outcomes Versus Using a Sequential BTKi in CLL/SLL | bernadette lazar | Received |
173-EP | Venetoclax; Implementation of Out-Patient Monitoring | Tracey Arthur | Received |
174-EP | Beyond Hospital Doors- Bringing Cancer Treatment to the patients own home; The Rotherham Experience | Suhani Ghiya | Received |
175-EP | A snapshot of UK clinical trial activity in myeloma: reflections on recruitment and patient experience | Rhys Owens | Received |
176-EP | Management of Monoclonal Gammopathy of Undetermined Significance Patient Group, by Haematology Advanced Nurse Practitioners. | Katharine Hanlon | Received |
177-EP | Real World Characteristics and Outcomes for Triple Class Exposed Myeloma Patients on Pomalidomide and Dexamethasone | Carmen Tsang | Received |
178-EP | Characteristics of Newly Diagnosed Myeloma Patients With and Without Transplant: Real-world Big Data From England | Sheetal Fermahan | Received |
179-EP | A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: in treatment-naïve chronic lymphocytic leukemia. | Miguel Miranda | Received |
180-EP | Real-World Outcomes of Triple-Class Exposed Patients with Relapsed Multiple Myeloma in England: Follow-up Analysis | Annie LIED-LIED | Received |
181-EP | Multiple Myeloma with Central Nervous System Disease: Three Cases From Nottingham City Hospital | Jennifer Ryan | Received |
182-EP | Paraneoplastic Granulocyte Colony-Stimulating Factor Secretion in a Patient with Multiple Myeloma - A Case Report. | Rebekah Picken | Received |
183-EP | Audit of thromboprophylaxis prescription in multiple myeloma patients receiving immunomodulatory-drug therapy | Niharika Manu | Received |
184-EP | Incidentalomas in patients with multiple myeloma, MGUS, and plasmacytomas - results of 150 PET-CTs | Catherine Chinnery | Received |
185-EP | Teclistamab Monotherapy First Experience in Patient with Refractory Multiple Myeloma in Russia | Stanislav Kamyshanov | Received |
186-EP | Newly Diagnosed Multiple Myeloma VRD Protocol Treatment Precursory Results | Arman Arakelyan | Received |
187-EP | Venetoclax Obinutuzumab for Chronic Lymphocytic Leukaemia: Is stringent TLS monitoring proportional to risk? | Thomas Mayo | Received |
188-EP | EPIC: A Non-Interventional Cohort Study of Patients with Chronic Lymphocytic Leukaemia Treated with First-Line Acalabrutinib | Renata Walewska | Received |
189-EP | Experience of the use of Belantamab Mafodotin in a UK Teaching Hospital | Aritri Mandal | Received |
190-EP | Venetoclax Effectiveness After Bruton Tyrosine Kinase Inhibitors In Chronic Lymphocytic Leukaemia: An International Real-World Study | bernadette lazar | Received |
191-EP | Myeloma masquerading as Myeloproliferative Neoplasm (MPN) A Case Report | Katarina Flatman | Received |
192-EP | Single-centre outcomes for high and ultra-high risk myeloma patients since the introduction of lenalidomide maintenance | Jennifer Ryan | Received |
193-EP | Pirtobrutinib in Post-cBTKi CLL/SLL With/Without Prior BCL2i: Phase 1/2 BRUIN Study 30 Months Follow-Up Analysis | Huseini Kagdi | Received |
194-EP | Genomic Evolution/Resistance during Pirtobrutinib therapy in Covalent BTK-Inhibitor (cBTKi) Pre-treated Chronic Lymphocytic Leukemia Patients (Update) | Huseini Kagdi | Received |
196-EP | Assigning Disease Risk in New Multiple Myeloma: Improving Practice to Prepare for Risk-Adaptive Treatment Strategies | Amalachukwu Nwosu | Received |
197-EP | Impact of Obesity on Melphalan Dosing in Myeloma Patients undergoing Autologous Stem Cell Transplantation. | Imogen Welding | Received |
198-EP | Real-World Experience of Implementation of Quadruplet Chemotherapy for Myeloma Patients in an NHS Cancer Centre. | Salam Youssef | Received |
199-EP | Initial findings from a first-in-human Phase 1a/b trial of NX-5948, a ive BTK degrader | Lee Miller | Received |
200-EP | Targeted Use of RNA Fusion Panels in the Diagnostic Work-Up of Selected Haematological Malignancies | Oliver Firth | Received |
201-EP | Is It A Major Or Minor Problem? Transfusion Errors In Haemopoietic Stem Cell Transplants 2011-2022 | Victoria Tuckley | Received |
28-30 April Liverpool
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|